iXB 321

iXB 321 is an investigational influenza vaccine developed by iX Biopharma using its proprietary WaferiX sublingual wafer delivery platform. The WaferiX technology utilizes a freeze-drying process to create a fast-dissolving wafer that disintegrates under the tongue within seconds, allowing for rapid absorption of the active ingredient through the sublingual mucosa. This needle-free administration method is designed to improve patient compliance and provide an alternative to traditional injectable vaccines. iXB 321 is currently in the early stages of development within the company's immunology and infectious disease pipeline.